Matt Kaeberlein, Ph.D.

Matt Kaeberlein, Ph.D.

Matt Kaeberlein, Ph.D., University of Washington

Aim: Examine and compare the effects of in-chow of 42mg/kg/day of rapamycin (42 ppm eRAPA) for 8 weeks (~2 months) on age-associated periodontal disease in wild-type C57BL/6 mice at 20 months of age.

Recently, we have shown that 90 days of rapamycin injection (8mg/kg/day) is sufficient to increase lifespan, healthspan, and remodel the microbiome. Also, we have recently published data that has shown that even at much lower doses in-chow 14mg/kg/day of rapamycin attenuated alveolar bone loss in age-associated periodontal disease in rapidly as 8 weeks in C57BL/6 mice. The aim of this experiment is to examine and compare the effects of in-chow of 42mg/kg/day of rapamycin (42 ppm eRAPA) for 8 weeks (~2 months) on age-associated periodontal disease in wild-type C57BL/6 mice at 20 months of age. We have decided on these doses and regimen because the in-chow 42 ppm eRAPA was the dose that has provided maximum lifespan extension in NIA Interventions Testing Program studies, and because there is a large body of published data demonstration efficacy utilizing this dietary rapamycin formulation. Our specific aim is to examine and compare in-chow 42mg/kg/day of rapamycin (8 weeks treatment) on age-associated periodontal disease in aged, wild type C57BL/6 mice starting at around 20 months of age.  Further, we also want to quantify age-associated periodontal disease and microbiome changes in young and middle-aged animals as baseline normative aging controls.